Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | Auto-HSCT in AL amyloidosis

Eli Muchtar • 9 Sep 2020
ISA 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Daratumumab

Autologous stem cell transplant (ASCT) has been utilized in the management of immunoglobulin light chain (AL) amyloidosis for several decades. The use of ASCT has been associated with high rates of hematologic response and improvement in organ function. However, novel agents have challenged the use of ASCT. Eli Muchtar, MD, Mayo Clinic, Rochester, MN, discusses the burning questions in the use of ASCT in AL amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Eli Muchtar

1:43
Feasibility of double autologous stem cell transplantation in patients with AL amyloidosis
Eli Muchtar • 6 Sep 2022
1:02
Incidence of hypovitaminosis D in patients with renal AL amyloidosis
Eli Muchtar • 6 Sep 2022
2:18
Using AI to predict light chain amyloidosis in patients with MGUS and SMM
Eli Muchtar • 6 Sep 2022
4:51
Localized amyloidosis: symptoms and site of disease
Eli Muchtar • 9 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals